Lafutidine-based triple therapy for Helicobacter pylori eradication

Area of Science:

• Gastroenterology
• Pharmacology
• Infectious Diseases

Background:

• The efficacy of H2-receptor antagonists versus proton pump inhibitors for Helicobacter pylori infection remains under investigation.
• Lafutidine, a novel H2-receptor antagonist, possesses demonstrated antisecretory properties.
• This meta-analysis evaluates lafutidine-based triple therapy for H. pylori eradication.

Purpose of the Study:

• To compare the efficacy and safety of lafutidine-based triple therapy with lansoprazole-based therapy for H. pylori eradication.
• To assess the role of lafutidine as an alternative to proton pump inhibitors in H. pylori treatment regimens.

Main Methods:

• A systematic meta-analysis of randomized controlled trials.
• Searched major databases including PubMed, EMBASE, Cochrane Library, and Chinese Biomedical Database.
• Included studies focused on lafutidine-based triple therapy for H. pylori eradication.

Main Results:

• Three randomized controlled trials met the inclusion criteria.
• Helicobacter pylori eradication rates were similar between lafutidine and lansoprazole groups (OR, 1.03; 95% CI, 0.64-1.66).
• Active ulcer cure rates, symptom response, and adverse events were comparable between the two treatment groups.

Conclusions:

• Lafutidine-based triple therapy is a safe and effective option for H. pylori infection, comparable to lansoprazole-based regimens.
• Lafutidine can be considered an additional treatment choice for H. pylori eradication.
• Further rigorous research is needed to fully establish lafutidine's role in H. pylori treatment.